Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BNT141 in CLDN18.2-positive solid tumors
NL-OMON53640Phase 1Not yet recruiting
- Sponsor
- BioNTech SE
- Start
- Sep 2023
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of BNT141 in Nonhematologic neoplasms, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 8 more (4 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-emergent adverse events, Dose reductions and discontinuations due to TEAEs and 1 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
BNT141
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON53640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53640.